Now, let's talk through how to best manage your hemophilia through this procedure.

Hello.

I'm Robert Klamroth, head of the Department of Internal Medicine at the Vivantes Hospital Friedrichshain in Berlin, Germany, and the director of the Hemophilia Treatment Center.

The scene you just watched highlights one of the important issues in hemophilia care.

Synovitis can still occur in patients receiving prophylaxis.

And we have a higher rate than expected in patients on prophylaxis of synovitis because we did a study in Germany with an ultrasound evaluation of joints, and there's synovial hypertrophy in more patients on prophylaxis than we expected.

Synovitis can occur after any bleeding event, including traumatic bleeds, and if you have microbleeds or unrecognized bleeds, that can also lead to synovitis.

Uh, thank you, Dr. Müller.

Robert, would you be able to start us off with an overview of the hemophilia A and the therapies currently available for our patients?

Yeah.

Hi, Cédric.

Surely.

It's a pleasure to be here with you and give some education about normalization in hemophilia A.

So hemophilia is, uh, hemophilia is that we don't have enough factor VIII, and the disease severity is defined by factor levels and the clinical bleeding phenotype.

And if you have no factor VIII at all, it's severe hemophilia, and it's moderate hemophilia up to five percent and mild hemophilia up to 30%.

What does normalizing hemostasis in hemophilia mean in 2026?